Susvimo: The Refillable Eye Implant That Can Cut Injections to Twice a Year
Susvimo at a Glance: An Implant Instead of Frequent Injections
Susvimo is a tiny implant placed in the eye during a short surgery. It slowly releases medicine for months. Many people can then go about six months between treatments. That is a big change from a shot every one to two months. Susvimo holds and steadily releases ranibizumab, an anti-VEGF medicine used for wet AMD and some diabetic eye disease1. It is meant for people who have already been helped by at least two anti-VEGF shots1. It does not cure the disease. It is a new way to give the same medicine, with fewer visits.
The appeal is the schedule. Standard anti-VEGF treatment for wet AMD often means frequent trips for injections, which is a real burden over years. In its main wet AMD trial, the implant refilled every 24 weeks, about twice a year, gave vision results that were noninferior to monthly ranibizumab injections2. For someone doing well on injections but tired of the frequency, trading many needle visits for two refill visits a year can be a meaningful change. The medicine keeps working in between because the implant releases it steadily rather than in single doses.
Fewer visits come with a different risk profile, and this is the heart of the decision. The Susvimo implant has been linked to an up to three-times-higher rate of endophthalmitis, a serious infection inside the eye, than monthly ranibizumab injections, and many of those infections followed a problem with the tissue covering the implant1. That risk is still uncommon, and steps are taken to lower it, but it is not zero and it is higher than with injections. Weighing fewer visits against this added risk, with your retina surgeon, is what the choice comes down to.
What Susvimo Is and How It Differs From Regular Injections
Susvimo is a small, permanent implant, roughly the size of a grain of rice, set into the wall of the eye where it is hidden under the eyelid and by a thin layer of tissue. The implant holds a reservoir of ranibizumab that is released continuously into the vitreous, the jelly inside the eye, and is topped up during in-office refill-exchange visits rather than replaced1. Unlike a single injection that delivers one dose and fades over weeks, the implant provides a steady supply. This continuous delivery is what allows the long gaps between treatments.
The drug in Susvimo is not new. Susvimo delivers ranibizumab, the same anti-VEGF medicine long used as an intravitreal injection to treat wet AMD by blocking vascular endothelial growth factor, the signal that drives leaky abnormal blood vessels3. What is different is only the delivery method: a refillable implant instead of repeated injections. Because the active medicine is familiar and well studied, most of the new considerations with Susvimo come from the implant and the surgery, not from the drug itself.
Susvimo is not a first treatment for a newly diagnosed eye. Per its label, Susvimo is for wet AMD, diabetic macular edema, and diabetic retinopathy in people who have already responded to at least two anti-VEGF injections, so it is a step for those already known to benefit from this class of medicine1. Requiring a prior response matters, because it confirms the disease reacts to anti-VEGF treatment before committing to a surgical implant. If injections have not helped your eye, Susvimo is unlikely to be offered.
How the Implant and Refills Actually Work
Placing Susvimo is a one-time procedure done as outpatient surgery, usually with numbing and sedation rather than general anesthesia. A retina surgeon makes a small opening in the wall of the eye and secures the implant, then closes the conjunctiva and underlying tissue carefully over it, because a secure covering helps lower the risk of later infection1. The surgery itself takes under an hour in most cases. Careful closure of the tissue over the implant is emphasized, since problems with that covering are tied to the most serious complication.
Once placed, the implant does the daily work for you. It releases ranibizumab slowly and steadily into the eye, keeping a working level of medicine present without any action on your part. This is the opposite of the injection pattern, where the dose peaks and then falls until the next visit. The steady release is the reason many eyes stay controlled for months at a time. You do not feel the implant working, and after healing most people are not aware of it in daily life.
The implant is refilled, not removed, when the medicine runs low. During a refill-exchange, done in the office with a special needle through the same implant, old fluid is swapped for a fresh supply of ranibizumab, and for wet AMD this is scheduled about every 24 weeks, roughly twice a year1. The refill is quick and uses numbing, similar in feel to an injection visit but far less often. Intervals differ by condition, so your own refill schedule depends on why you are being treated and how your eye responds.
Who Is a Good Candidate for Susvimo
The clearest candidate is someone whose eye already does well on injections but who wants fewer of them. Because Susvimo is labeled for people who have responded to at least two prior anti-VEGF injections, a proven response to the medicine is the starting point for considering it1. If your wet AMD or diabetic eye disease has been controlled by injections, you have the response that Susvimo builds on. This is why it is described as a way to change how you receive a treatment that is already helping, not as a rescue for treatment that has failed.
Susvimo is not right for everyone. People uneasy about eye surgery, or about a higher infection risk in exchange for fewer visits, may reasonably prefer to continue injections. Those who cannot commit to prompt follow-up if a problem arises may also be safer with the standard approach, since the implant needs watching. And anyone whose disease is not clearly anti-VEGF responsive is not a candidate. The choice is genuinely personal, balancing how much the frequent injections bother you against your comfort with surgery and monitoring.
Practical life factors matter in this decision. If travel, work, or caregiving makes frequent injection visits hard, the twice-a-year rhythm can be a strong draw. On the other hand, the implant asks you to notice and report eye changes quickly and to keep your refill and check appointments reliably. If you have good support and stable access to your retina clinic, that is a point in favor. Bring your real routine to the conversation, since the best answer often depends on your day-to-day life as much as your eye.
What to Settle at the Consultation
The most important thing to understand before agreeing is the infection risk. The implant carries an up to three-times-higher rate of endophthalmitis than monthly injections, about 2 of every 100 eyes with the implant versus roughly 1 of every 200 with injections in the controlled trial period1. Ask your surgeon how they lower this risk and what the warning signs are. Understanding this clearly, rather than being surprised by it later, is part of giving informed consent for a device that trades convenience for a specific added risk.
It helps to picture the whole commitment, not just the surgery. You will heal from an outpatient operation, attend refill visits about twice a year for wet AMD, and come in promptly if anything changes. Ask what activity limits to expect at first, how the implant might look or feel, and what to do if you notice redness or a bump at the implant site. Settling these details up front means the routine holds no surprises, and it lets you judge honestly whether the trade of fewer injections for this care plan fits you.
When Susvimo Should Not Be Used
Some situations make the implant unsafe to place or refill. Susvimo should not be used when there is an infection in or around the eye or active inflammation inside the eye, because placing a device in that setting raises the danger of a serious infection1. If you have a red, painful, or infected eye, the procedure would be delayed until it clears. This is standard caution for any eye surgery, and it protects you from turning a treatable surface problem into a deep one.
A known allergy to the medicine rules it out. Susvimo is not used in people with a known hypersensitivity to ranibizumab or to the implant's other ingredients1. Beyond that, your surgeon weighs your eye anatomy, your ability to attend follow-up, and any prior eye surgeries when judging whether the implant is a safe fit. If any of these raise concern, standard injections remain a well-proven option, so ruling out the implant does not mean ruling out effective treatment.
Recovery After the Implant Surgery
Early recovery is similar to other eye surgery. You can expect some redness, mild soreness, a scratchy feeling, and a small red patch on the white of the eye that fades over days. Your surgeon will prescribe drops and usually ask you to avoid rubbing the eye, heavy lifting, and swimming for a period while the tissue over the implant heals. Vision may be blurry at first and then settle. Follow the specific instructions you are given closely, because good healing of the tissue covering the implant is what protects against later trouble.
After healing, the implant is meant to stay quietly in place. Because many serious infections followed erosion or pulling back of the tissue covering the implant, catching and repairing any such change early is part of keeping the implant safe over time1. In practice this means keeping your check-ups and reporting any new redness, discomfort, or a visible change at the implant site promptly. The implant is low-maintenance day to day, but it is not something to ignore, and steady follow-up is the price of the longer gaps between treatments.
Risks, Complications, and What Results to Expect
The two risks that most define Susvimo are linked. Conjunctival erosion, where the tissue over the implant thins or pulls back, occurred in about 4 of every 100 eyes with wet AMD, and it can precede endophthalmitis, the serious inner-eye infection the implant raises the risk of1. Both are uncommon, and surgeons use careful technique and early repair to reduce them. Still, they are the reason the implant demands attentive follow-up. Knowing these signs and acting on them quickly is the single most useful thing a Susvimo patient can do.
As with any eye surgery, other complications are possible. These can include bleeding inside the eye, a leak of fluid, movement of the implant, cataract, retinal detachment, or eye pain. Most are uncommon, and many are manageable when caught early. Your surgeon will review the specific risks that apply to your eye. The point is not that Susvimo is dangerous, but that it is a surgical device, so it carries surgical risks that a simple injection does not, and those belong in your decision.
On the benefit side, the vision results are reassuring. In the main wet AMD trial, people were assigned in a 3-to-2 split to the implant refilled every 24 weeks or to monthly ranibizumab injections, and the implant group kept vision that was equivalent to and noninferior to the monthly injection group2. In plain terms, the implant held vision about as well as the intensive injection schedule, but with far fewer treatment visits. It does not promise better vision than injections. Its advantage is matching those results with much less frequent care.
Warning Signs to Report Right Away
Certain symptoms after implant surgery or a refill call for a same-day contact with your eye doctor or surgeon, not a wait-and-see. Reach out right away if you notice any of these:
- Increasing eye pain, or pain that returns after settling.
- Growing redness, new discharge, or a bump or opening at the implant site.
- Vision that is getting worse, or a new dark shadow or curtain.
- A sudden burst of new floaters, or new flashing lights.
These signs do not always mean infection, and getting checked often brings relief, but only a prompt exam can tell. Because the implant raises the infection risk, fast action is exactly how a rare problem is kept from causing lasting harm.
Not every change is an emergency, but some deserve a call before your next scheduled visit. A gradual increase in blur, new distortion where straight lines look bent, or a persistent scratchy feeling or visible change over the implant are worth reporting soon. Catching a returning disease flare, or an early problem with the tissue over the implant, lets your team act while options are simplest. When you are unsure how urgent something is, call and describe it, and let the clinic decide how quickly you should be seen.
Common Questions About Susvimo
No. Susvimo controls the disease rather than curing it, the same as anti-VEGF injections do. It delivers medicine continuously to keep abnormal blood vessels calm, but the underlying condition remains, which is why the implant is refilled on a schedule rather than removed once things improve. Think of it as a lower-maintenance way to keep treating a chronic condition, not a one-time fix. If treatment stops entirely, the disease can become active again, so ongoing care continues even with the implant in place.
For wet AMD, the implant is typically refilled about every 24 weeks, or roughly twice a year, which is far less often than the monthly to every-other-month injections many people receive. You will also have monitoring checks in between, and you should come in promptly if anything changes. Refill intervals differ for diabetic conditions, so your exact schedule depends on why you are treated and how your eye responds. The headline benefit is fewer treatment visits, but not zero contact with your retina clinic.
Yes. Susvimo was voluntarily recalled in October 2022 after testing found that the seal, or septum, on some implants did not hold up to repeated refills as well as required. Genentech later updated the implant and refill needle, testing confirmed the updated components met performance standards, and Susvimo was reintroduced in the United States in 20244. If you are considering it now, this history is worth discussing with your surgeon, who can explain the current device and what the update changed.
Generally not in normal circumstances. The implant sits in the upper part of the eye, tucked under the eyelid and covered by a thin layer of tissue, so it is usually hidden from view. A careful look with the eye turned may reveal a small area, but in day-to-day life most people and most observers are unaware of it. If you notice the covering tissue changing, thinning, or a bump becoming visible, that is a reason to call your doctor rather than a normal appearance.
The implant is placed during surgery with numbing and usually sedation, so you should not feel pain during the procedure, though some soreness afterward is normal. The refill-exchange visits are done in the office with numbing and a special needle, and most people find them comparable to an injection visit but far less frequent. If you have significant pain at any point, especially pain that increases after the first day, that is not expected and should prompt a same-day call to your eye doctor.
Yes, removal is possible, and your surgeon can discuss what that involves and when it might be advised, such as certain complications. Removing or exchanging the implant is another surgical procedure with its own considerations, so it is not done lightly, but the option exists. This is a good topic for your consultation. Understanding in advance what happens if the implant needs to come out, or if you decide to return to injections, helps you enter the decision with a full picture.
More Questions About Living With the Implant
Not necessarily better, but comparable. In its main wet AMD trial, the implant held vision that was equivalent to monthly injections, so the goal is to match those results, not to beat them. The real advantage is achieving similar vision with far fewer treatment visits. If your main hope is sharper vision than injections give, the implant is unlikely to deliver that. If your hope is to keep your current results with much less frequent care, that is exactly what it aims to offer.
Between refills, your retina team checks that the disease stays controlled and that the implant and the tissue over it look healthy. This usually includes a vision check, an eye exam, and imaging of the retina to look for any returning fluid. These visits are how problems are caught early, whether a disease flare or an early change over the implant. They are shorter and involve no treatment when all is well, but they are an important part of the plan, so keeping them matters even during good stretches.
Possibly. Susvimo is labeled for diabetic macular edema and diabetic retinopathy as well as wet AMD, again for people who have already responded to anti-VEGF injections. The refill schedule can differ for diabetic conditions. Whether it suits you depends on your specific diagnosis, how your eye has responded to injections, and your comfort with the surgery and follow-up. Your retina specialist can tell you whether your diabetic eye disease fits the situations where the implant is used and whether it is a sensible option for you.
Possibly, since each eye is treated on its own. If only one eye has the implant, the other eye is managed separately based on its own condition and may still need injections or its own treatment plan. The implant in one eye does not treat the other. Your retina doctor watches both eyes at your visits and tailors care to each. It is common for people to have different treatments in each eye, so this is a normal situation rather than a sign that something is wrong.
- Am I a good candidate for Susvimo based on how my eye has responded?
- How do you lower the infection risk during surgery and refills?
- What are the exact warning signs that should make me call you the same day?
- How often will I need refills and monitoring visits for my condition?
- What are my options if I have a complication or want the implant removed?
- How does the current implant differ from the one recalled in 2022?
- U.S. FDA prescribing label via DailyMed (2025). SUSVIMO (ranibizumab injection) prescribing information.
- Ophthalmology (Holekamp NM et al, Archway Investigators) (2023). Archway Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular AMD: 2-Year Results.
- American Society of Retina Specialists (ASRS) (2024). Age-Related Macular Degeneration (patient information).
- Ophthalmology Times (2024). Genentech receives FDA approval to relaunch Susvimo.